Entrada Therapeutics Inc(TRDA)
$4.35-0.29 (-6.25%)
TRDA
Entrada Therapeutics Inc stock drug pipeline
$4.35
At close:-0.29 (-6.25%)
Want to see TRDA full AI Analyst Report?
Entrada Therapeutics Inc (TRDA) Drug Pipeline
164 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Entr-601-45 | Duchenne Muscular Dystrophy (Dmd) | phase1AndPhase2 | Not Yet Recruiting | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | May 01, 2025 | ― |
| Entr-601-44 | Duchenne Muscular Dystrophy (Dmd) | phase1AndPhase2 | Recruiting | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | May 01, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Entr-601-45 | phase1AndPhase2 | Duchenne Muscular Dystrophy (Dmd) | Not Yet Recruiting | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | May 01, 2025 | ― |
| Entr-601-44 | phase1AndPhase2 | Duchenne Muscular Dystrophy (Dmd) | Recruiting | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | May 01, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Entrada Therapeutics Inc (TRDA) have in its pipeline
Entrada Therapeutics Inc TRDA is currently developing the following drugs: Entr-601-45, Entr-601-44. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
